Company news

Apellis Pharmaceuticals, Inc. news in 2024

Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

November 11, 2024

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 4, 2024

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

October 25, 2024

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

October 21, 2024

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

October 15, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

September 24, 2024

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

September 19, 2024

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

August 7, 2024

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

August 7, 2024

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

July 31, 2024

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

July 17, 2024

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

July 8, 2024

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

June 27, 2024

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

June 9, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

May 23, 2024

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street

May 13, 2024

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

May 6, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

May 5, 2024

Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 30, 2024

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

April 25, 2024

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

April 22, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

March 10, 2024

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 19, 2024

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

January 25, 2024

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

January 7, 2024

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Calls in 2024

Decks in 2024